Andexxa | Drug Injury Watch

Andexxa Drug Recall December 2025 Due In Part To Safety Issue That Involves Blood Clots

December 15, 2025

High Rate Of Thrombotic Events And More Thrombosis-related Deaths Compared To Standard Antidote Treatment (Posted by Tom Lamb at Drug Injury Watch) UPDATE: Andexxa FDA Safety Communication Issued In December 2025 “Based on available data, the serious…

Possible Andexxa Recall After FDA Does Not Approve the Anticoagulant Reversal Drug in December 2024

January 3, 2025

AstraZeneca Says “while discussions with the FDA are ongoing, Andexxa will remain on the US market.” (Posted by Tom Lamb at Drug Injury Watch) In our November 21, 2024, article, “Do Andexxa Risks Outweigh Benefits Given Increased…

Do Andexxa Risks Outweigh Benefits Given Increased Rate of Thrombosis and Thrombosis-Related Deaths?

November 21, 2024

Issue to be Considered by FDA Advisory Committee on November 21, 2024, and Discussion May Lead to Andexxa Drug Recall (Posted by Tom Lamb at Drug Injury Watch) At its November 21, 2024 meeting, the FDA’s Cellular,…

Xarelto / Savaysa / Eliquis: Antidote Drug AndexXa Is Rejected By FDA In August 2016, Surprising Many Pharma Industry Observers (And Doctors?)

August 22, 2016

Portola, Which Developed AndexXa, Estimates 100,000 Patients Per Year Suffer From Severe Uncontrollable Bleeding Events That Could Require Such An Antidote (Posted by Tom Lamb at DrugInjuryWatch.com) In mid-August 2016 the US…

Tag: Andexxa

Andexxa Drug Recall December 2025 Due In Part To Safety Issue That Involves Blood Clots

Possible Andexxa Recall After FDA Does Not Approve the Anticoagulant Reversal Drug in December 2024

Do Andexxa Risks Outweigh Benefits Given Increased Rate of Thrombosis and Thrombosis-Related Deaths?

Xarelto / Savaysa / Eliquis: Antidote Drug AndexXa Is Rejected By FDA In August 2016, Surprising Many Pharma Industry Observers (And Doctors?)